Abstract: Prolonged parenteral release into the circulatory system of a cow of a bioactive bovine somatotropin at desirably effective levels can be achieved using novel compositions in which the bovine somatotropin is present in an aqueous liquid at a dose of at least about 150 mg and at a concentration of at least about 50 mg/ml. The aqueous bovine somatotropin formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than three (3) days.

Abstract: Disclosed is an improved process for the preparation of carbamates by heating an organic carbonate and an aromatic urea or polyurea in the presence of aluminum as catalyst and a promoter comprising a combination of iodine and a mercury salt.High reaction temperatures are avoided by the process and conversions to carbamate products are high. Additionally, the process is economically attractive because even the common aluminum foil can be used as the catalyst.The products prepared by the process can be used in the production of insecticides, and, particularly, as intermediates in the preparation of organic mono- and polyisocyanates.

Abstract: Blends are disclosed of a clear polyurethane plastic and a minor amount (up to 30 parts by weight per 100 parts by weight of blend) of an incompatible polymeric impact modifier. The resulting blends exhibit properties (high impact resistance, high flexural modulus and resistance to heat) comparable to those of engineering plastics such as nylon.

Abstract: A process for increased productivity in healthy animals comprising the administration of a compound of the formula ##STR1## or a pharmacologically acceptable acid addition salt thereof wherein R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of lower alkyl of from 1 to 4 carbon atoms; R.sub.3 and R.sub.4 are the same or different and are selected from the group consisting of hydrogen, halogen, and lower alkyl of from 1 to 4 carbon atoms, and n is 1 or 2 provided that when n is 2 then R.sub.1 and R.sub.2 are the same and R.sub.3 and R.sub.4 are the same, in association with the animal feed, water, salt rations, or pharmacologically acceptable carrier. Compositions comprising a compound of the above formula for daily administration or long acting forms are disclosed.

Abstract: Pharmaceutical compositions comprising, in unit dosage form, from about 0.5 mg. to about 100 mg. of a compound of the formula: ##SPC1##Wherein R, R.sub.1, R.sub.2 and R.sub.3 are hydrogen, methyl or ethyl, and R.sub.4 is hydrogen, fluorine, chlorine, bromine, --NO.sub.2, --CF.sub.3, or methylthio, inclusive; including the pharmacologically acceptable acid addition salts thereof, in association with a pharmaceutical carrier. The process is the administration of the above compositions to humans at a dose of from about 0.1 mg./kg./day to about 10 mg./kg./day for anti-depressant therapy with minimum sedative side-effects.